Health care sector, being one of the biggest and highly complex industries, consist of a broad spectrum of companies that are involved in the marketing and selling of medical products and services. This segment includes companies that sell pharmaceutical products, provides treatments to patients, hospital and health care practitioners. The companies providing services like insurance, medical care and other related products also come under the health care sector.
The health care industries can be subcategorised into the following-
- Pharma & Biotech industry- All the pharmaceutical and biotech companies which are involved in the manufacturing of pharmaceutical, as well as generic drugs, fall in this category. The pharma and biotech industries engage in the R&D for creating new and innovative medicines, medical devices and method of treatment. However, the market value of these companies may depend on the expectation that a drug formulation will obtain approval from a regulatory authority such as FDA or TGA and more.
- Medical device providers- Medical device manufacturers vary from companies that are involved in manufacturing standard, familiar products such as bandages, gloves, forceps, and scalpels, to firms that conduct cutting-edge research and produce exclusive, hi-tech equipment, like Magnetic resonance imaging (MRI) machines and surgical equipments.
- Health insurance providers- Health care insurance provider companies, come under the category of managed health care and provide different type of health insurance policies according to the plan opted by the policyholder.
- Health care facilities- Health care facilities providers include clinics, psychiatric facilities, laboratories, hospitals, as well as nursing homes.
In this article, we are discussing four health care sector stocks- PNV, OPT, NAN, AVH
PolyNovo Limited (ASX: PNV)
An Australian based ASX listed health care sector player PolyNovo Limited (ASX: PNV) is a medical device company that is engaged in the development of dermal regeneration solutions named as NovoSorb BTM by applying its patented biodegradable polymer technology NovoSorb. The company manufactures devices for Hernia, Breast Sling and Orthopaedic applications.
White Island Tragedy
According to one ASX announcement dated 16 December 2019, PolyNovo has provided its NovoSorb BTM technology in two Australian and three New Zealand hospitals to support and provide the best opportunity for dermal repair. The nursing, as well as surgical teams, have established clinical capability in applying NovoSorb BTM to ensure the best clinical results for these patients.
White Island Tragedy recently happened in New Zealand and is a challenging condition for all who are affected. In hospitals of Australia and New Zealand, various trauma and surgical teams have put in courageous attempts and several hours to support and help these patients.
On 03 January 2019, the PNV’s stock settled the day’s trade at $1.870, up 0.8%. PNV’s market capitalisation stood at around $1.23 billion, with nearly 661.09 million shares outstanding. The 52 weeks high and low price of the stock was noted at $2.660 and $0.580, respectively.
Opthea Limited (ASX: OPT)
A health care company Opthea Limited (ASX: OPT) which was formerly known as Circadian Technologies, is engaged in developing biologics for ophthalmic diseases. The company has exclusive global rights to a considerable intellectual property (IP) portfolio for Vascular endothelial growth factors as well as Vascular endothelial growth factor receptor- VEGF-C, VEGF-D, VEGFR-3. The developmental programs of Opthea are centred on OPT-302 for retinal eye disorders, including Diabetic Macular Edema (DME) and wet Age-related Macular Degeneration (wet- AMD).
The existing therapies for ophthalmic diseases primarily target VEGF-A, however; Opthea’s lead compound OPT-302 acts as an inhibitor of VEGF-C/VEGF-D and prevents the development of blood and lymphatic vessel, as well as inhibit leakage of vessel. The figure below represents how OPT-302 acts by inhibiting VEGF-C and VEGF-D.
Institutional Placement of $50 million
On 6 December 2019, Opthea revealed about the completion of the private placement, which was previously announced on 2 December 2019, and raised $50 million by issuing approximately 18.9 million fully paid ordinary shares at an issue price of $2.65/new share. The existing Opthea shares and the New Shares issued under the placement both ranks equally.
On 03 January 2019, OPT’s stock settled the day’s trade at $2.860, edging downwards by 2.05%. OPT’s market capitalisation stood at around $785.94 million, with nearly 269.16 million shares outstanding. The 52 weeks high and low price of the stock was noted at $4.150 and $0.565, respectively.
Nanosonics Limited (ASX: NAN)
New South Wales headquartered ASX listed health care company Nanosonics Limited (ASX: NAN) is an innovator in the prevention of infection. Nanosonics has a well experienced team of more than 200 specialists who are dedicated to delivering HLD solutions for ultrasound probe use.
Nanosonic’s automated and unique trophon® EPR high-level disinfection device laid the foundation across the globe in setting a new standard of care in ultrasound probe disinfection systems.
The company updated the market with its Annual General Meeting (AGM) presentation in November 2019 and discussed the financial performance during FY2019, including its business outcome for upcoming years. The quick highlights of FY2020 outlook are-
- In the financial year 2020, the company would continue to grow in the installed base in North America with adoption like financial year 2019.
- Nanosonic foresees accelerated investment in growth with the total fiscal year 2020 operating expenses anticipated to be nearly $67 million, which includes around $15 million in research and developments.
- Introduction of significant new product commercially to begin in the financial year 2021 and launch in several global markets during the first half of the financial year 2021.
- Beyond 2020, the company anticipates the launch of its expanded product portfolio at the global level and continued investment in research and development to build a pipeline of innovative potential product opportunities.
- Japan to turn out to be an essential growth market for trophon and further expansion into the Asia Pacific is expected beyond 2020.
On 03 January 2019, NAN’s stock settled the day’s trade at $6.340, declined 0.314%. NAN’s market capitalisation stood at around $1.91 billion, with nearly 300.48 million shares outstanding. The 52 weeks high and low price of the stock was recorded at $7.600 and $2.740, respectively. The P/E ratio of the stock stands at 140.09x.
AVITA Medical Limited (ASX: AVH)
Biotechnology company AVITA Medical Limited (ASX: AVH) is engaged in the development of regenerative medicine for addressing the unmet medical needs in indications including chronic wounds, aesthetic and burns. The company develops medical devices based on its patented and proprietary application technology. AVITA’s devices work by preparing an autologous suspension of the patients own skin cells that are required for the regeneration of natural and healthy epidermis. This suspension is named as REGENERATIVE EPIDERMAL SUSPENSION™ or RES™.
USFDA Investigational Device Exemption Approval for RECELL System
On 30 December 2019, AVITA medical unveiled that the US FDA has approved the Investigational Device Exemption application for conducting a possibility study for evaluation of the effectiveness as well as safety of the RECELL® System for repigmentation of depigmented lesions that are related with vitiligo.
AVITA Medical would work in partnership with a prominent medical center for conducting a pilot study with ten patients having stable vitiligo lesions for a minimum one year. Vitiligo lesion affected areas would be randomly treated with the varying suspensions which are formulated by using RECELL to confirm the rate of response and optimal parameters for suspension.
On 03 January 2019, the AVH stock settled the day at $0.640, edging up by 0.787%. AVH’s market capitalisation stood at around $1.34 billion, with nearly 2.12 billion shares outstanding. The 52 weeks high and low price of the stock was noted at $0.740 and at $0.078 respectively.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.